Internship
Electronics Technician for Automation Technology Trainee
Updated on 9/3/2026
Evonik
10,001+ employees
Global specialty chemicals manufacturer and supplier
Compensation Overview
€1.1k/mo
Marl, Germany
In Person
 Electrical Engineering (1) |
|---|
Get referred to Evonik
See people who can refer or advise you
- Fachoberschulreife, Mittlere Reife, or a higher school-leaving qualification.
- Demonstrated enthusiasm for innovative technologies and technical-physical understanding.
- Accuracy, manual dexterity, and finger dexterity.
- Good, secure mathematics knowledge at the lower secondary level.
- Enjoyment of working with digital systems and applications.
- Logical thinking, care, ability to concentrate, and a sense of responsibility.
- Willingness to work and enthusiasm for teamwork.
- Secure color vision.
- Install, maintain, and service measurement, control, and regulating equipment on electrical production systems and process control systems.
- Measure physical quantities such as pressure, temperature, and flow, as well as electrical quantities such as currents and voltages.
- Maintain, repair, and test electrical systems.
- Create and expand control programs and program automated systems.
- Install and initialize operating systems, bus systems, and network technology.
- Optimize ongoing production processes and eliminate faults.
- Organize work processes and carry out projects in electrical and automation technology.
- Complete theoretical training at Hans-Böckler-Berufskolleg in Marl in subject-specific and general-education subjects.
Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.
Company Size
10,001+
Company Stage
IPO
Headquarters
Essen, Germany
Founded
2007
Get referred to Evonik
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 4, 2026 Q2 adjusted EBITDA rose 24% to €630 million, a four-year high.
- Evonik raised 2026 EBITDA guidance to €2.0-€2.2 billion after stronger volumes and pricing.
- Vancouver and Lafayette investments, announced August 27 and July 8, 2026, expand pharma capacity.
What critics are saying
- Reuters on June 18, 2026 said Evonik will cut 3,200 jobs through 2029.
- Evonik plans to discontinue polyester in 2027 after years of losses and failed buyer talks.
- Oxeno divestment and weak European margins expose Evonik to permanent portfolio shrinkage by 2027.
What makes Evonik unique
- Evonik’s 2026 portfolio shift targets specialty chemicals, not commodity volumes, unlike BASF or Solvay.
- Its Tippecanoe and Vancouver pharma CDMO assets anchor high-margin drug delivery and API services.
- Evonik’s AEM hydrogen membrane and Rocket recycling modules create proprietary process-technology adjacency.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
Parental Leave
Tuition Reimbursement
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Paid Vacation
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 11%Evonik is investing over C$150 million (€93 million) in a new GMP manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The Canadian federal government's Strategic Response Fund is supporting the project with up to C$68 million (around €42 million). The facility will more than triple Evonik's current production capacity for advanced pharmaceutical products, including vaccines and therapeutics. Drug product production is planned to begin at the end of 2029. The expansion builds on Evonik Vancouver Laboratories' expertise in lipid-based drug delivery since the 1990s. The site provides CDMO services for advanced LNP and liposomal delivery systems, from formulation research through GMP clinical trial manufacturing. The LNP market is projected to reach $2.7 billion by 2034, driven by growing demand for nucleic acid therapeutics.
Evonik reported a 24% surge in Q2 EBITDA, while the global polymeric surfactants market is projected to reach $17.8 billion by 2035, according to a new report from ResearchAndMarkets.com. The market was valued at $10.5 billion in 2025 and is expected to grow at a 5.4% CAGR through 2035. Growth is driven by the transition towards water-based and low-VOC systems in coatings, paints, personal care, and industrial applications. Block copolymers held a 42.2% market share in 2025, making them the leading product category. Their dominance stems from precise molecular structure control and versatility across multiple applications including coatings, pharmaceuticals, agriculture, and personal care. The personal care and cosmetics industry represents a key growth area, fuelled by consumer demand for premium products offering improved texture and stability. Manufacturers are increasingly incorporating polymeric surfactants into product development as regulatory requirements and sustainability objectives evolve.
Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.
Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.
German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.